Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology
- PMID: 17522387
- DOI: 10.1212/01.wnl.0000265517.66976.28
Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology
Erratum in
- Neurology. 2008 Apr 1;70(14):1223
Abstract
Objective: To provide evidence-based recommendations on the treatment of nervous system Lyme disease and post-Lyme syndrome. Three questions were addressed: 1) Which antimicrobial agents are effective? 2) Are different regimens preferred for different manifestations of nervous system Lyme disease? 3) What duration of therapy is needed?
Methods: The authors analyzed published studies (1983-2003) using a structured review process to classify the evidence related to the questions posed.
Results: The panel reviewed 353 abstracts which yielded 112 potentially relevant articles that were reviewed, from which 37 articles were identified that were included in the analysis.
Conclusions: There are sufficient data to conclude that, in both adults and children, this nervous system infection responds well to penicillin, ceftriaxone, cefotaxime, and doxycycline (Level B recommendation). Although most studies have used parenteral regimens for neuroborreliosis, several European studies support use of oral doxycycline in adults with meningitis, cranial neuritis, and radiculitis (Level B), reserving parenteral regimens for patients with parenchymal CNS involvement, other severe neurologic symptomatology, or failure to respond to oral regimens. The number of children (> or =8 years of age) enrolled in rigorous studies of oral vs parenteral regimens has been smaller, making conclusions less statistically compelling. However, all available data indicate results are comparable to those observed in adults. In contrast, there is no compelling evidence that prolonged treatment with antibiotics has any beneficial effect in post-Lyme syndrome (Level A).
Comment in
-
Re: Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. 2008 May 6;70(19):1719; author reply 1719-20. doi: 10.1212/01.wnl.0000313811.07154.89. Neurology. 2008. PMID: 18458234 No abstract available.
Similar articles
-
Antibiotics for the neurological complications of Lyme disease.Cochrane Database Syst Rev. 2016 Dec 8;12(12):CD006978. doi: 10.1002/14651858.CD006978.pub2. Cochrane Database Syst Rev. 2016. PMID: 27931077 Free PMC article. Review.
-
Neurologic Complications of Lyme Disease.Continuum (Minneap Minn). 2021 Aug 1;27(4):1040-1050. doi: 10.1212/CON.0000000000001015. Continuum (Minneap Minn). 2021. PMID: 34623103 Review.
-
Forty Years of Evidence on the Efficacy and Safety of Oral and Injectable Antibiotics for Treating Lyme Disease of Adults and Children: A Network Meta-Analysis.Microbiol Spectr. 2021 Dec 22;9(3):e0076121. doi: 10.1128/Spectrum.00761-21. Epub 2021 Nov 10. Microbiol Spectr. 2021. PMID: 34756070 Free PMC article.
-
Oral doxycycline for Lyme neuroborreliosis with symptoms of encephalitis, myelitis, vasculitis or intracranial hypertension.Eur J Neurol. 2014 Sep;21(9):1162-7. doi: 10.1111/ene.12420. Epub 2014 Mar 29. Eur J Neurol. 2014. PMID: 24684211
-
Six versus two weeks treatment with doxycycline in Lyme neuroborreliosis: the protocol of a multicentre, non-inferiority, double-blinded and randomised controlled trial.BMJ Open. 2019 Jun 14;9(6):e027083. doi: 10.1136/bmjopen-2018-027083. BMJ Open. 2019. PMID: 31201188 Free PMC article.
Cited by
-
Current and emerging approaches for eliminating Borrelia burgdorferi and alleviating persistent Lyme disease symptoms.Front Microbiol. 2024 Sep 13;15:1459202. doi: 10.3389/fmicb.2024.1459202. eCollection 2024. Front Microbiol. 2024. PMID: 39345262 Free PMC article. Review.
-
[Pathogen-induced diseases of the spinal cord and adjacent structures].Nervenarzt. 2024 Oct;95(10):948-956. doi: 10.1007/s00115-024-01743-0. Epub 2024 Sep 12. Nervenarzt. 2024. PMID: 39266688 German.
-
Lyme Disease and Papilledema: A Retrospective Study on Clinical Characteristics and Outcomes.J Child Neurol. 2024 Aug;39(9-10):334-342. doi: 10.1177/08830738241273376. Epub 2024 Sep 2. J Child Neurol. 2024. PMID: 39221464 Free PMC article.
-
Diagnostic Precision in Lyme borreliosis: Assessing VlsE and C6 Antigens in a Pediatric Cohort.Diagnostics (Basel). 2023 Nov 28;13(23):3547. doi: 10.3390/diagnostics13233547. Diagnostics (Basel). 2023. PMID: 38066788 Free PMC article.
-
Lyme Disease: An Overview.Indian Dermatol Online J. 2023 Feb 23;14(5):594-604. doi: 10.4103/idoj.idoj_418_22. eCollection 2023 Sep-Oct. Indian Dermatol Online J. 2023. PMID: 37727539 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical